Effect of Three Fibrate Derivatives and of Two HMG-CoA Reductase Inhibitors on Plasma Fibrinogen Level in Patients with Primary Hypercholesterolemia

Summary

In order to evaluate the effects of hypocholesterolemic drugs on plasma fibrinogen concentration, six groups of subjects with primary hypercholesterolemia have been put on treatment with diet alone or diet plus fenofibrate (100 mg t.i.d.), slow release bezafibrate (400 mg once a day), gemfibrozil (600 mg b.i.d.), simvastatin (20 mg once a day) or pravastatin (20 mg once a day) respectively. After 1 month of therapy, plasma fibrinogen significantly decreased by 9% and 15% in fenofibrate and bezafibrate groups respectively and increased by 19% in gemfibrozil treated patients. After 4 months of therapy the changes were −16% with fenofibrate, −10% with bezafibrate and +20% with gemfibrozil. No significant changes were observed in patients treated with diet alone, simvastatin or pravastatin. The fibrinogen lowering effect of fenofibrate and bezafibrate does not seem to be related to the hypolipidemic activity of the drugs.

• References

• 1 Kannel WB, Wolf PA, Castelli WP. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 1987; 258: 1183-1186
• 2 Wilhelmsen L, Svaerdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-504
• 3 Heinrich J, Schulte H, Balleisen L, Assmann G, Van de Loo J. Predictive value of haemostatic variables in the PROCAM-Study. Thromb Haemostas 1991; 65: 815
• 4 Handa K, Kono S, Arakawa K. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989; 77: 209-213
• 5 Lowe GDO, Drummond MM, Lorimer AR, Hutton I, Forbes CD, Prentice CRM, Barbenel JC. Relation between extent of coronary artery disease and blood viscosity. Br Med J 1980; 1: 673-674
• 6 Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, Miller GJ, North WRS, Stirling y, Thompson SG. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537
• 7 Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 19l6-1924
• 8 Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipoproteinemias. Bull WHO 1970; 43: 891-908
• 9 Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haemat 1957; 17: 237-240
• 10 Snedecor GW, Cochran WG. Statistical Methods. 6. Iowa State University Press: Ames, IA; 1967
• 11 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 19l-205
• 12 Ernst E. Plasma fibrinogen – an independent cardiovascular risk factor. J Intern Med 1990; 227: 365-372
• 13 Owen J, Grossman BA, Palmer RH. Hyperlipidemia and in vivo hemostatic system activation. Semin Thromb Hemostas 1988; 14: 241-245
• 14 Lowe GDO, Mc ArdleBM, Stromberg P, Lorimer AR, Forbes CD, Prentice CRM. Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinemia. Lancet 1982; ii: 472-474
• 15 Koppensteiner R, Minar E, Ehringer H. Effects of lovastatin on hemorheology in type II hyperlipoproteinemias. Atherosclerosis 1990; 83: 53-58
• 16 Bo M, Bonino E, Nierotti M, Gottero M, Pernigotti L, Molaschi M, Fabris F. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 1991; 42: 106-113
• 17 Jay RH, Rampling MW, Betteridge DJ. Abnormalities of blood rheology in familial hypercholesterolemia: effects of treatment. Atherosclerosis 1990; 85: 249-256
• 18 Leschke M, Hoffken H, Schmidtsdorff A, Blanke H, Eybring R, Joseph K, Strauer BE. The effect of fenofibrate on fibrinogen concentration and blood viscosity: its possible consequences for myocardial microcirculation in coronary heart disease. Dtsch Med Wschr 1989; 114: 939-944
• 19 Almer LD, Kjellstrom T. The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. Atherosclerosis 1986; 61: 81-85
• 20 Niort G, Bulgarelli A, Pagano A. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988; 7l: 113-119
• 21 Avellone G, DiGarbo V, Panno AV, Cordovo R, Lepore R, Strano A. Changes induced by gemfibrozil on lipid, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int Angiol 1988; 7: 270-277
• 22 Agrati AM, Ambrosi G, Ferraro G. Gemfibrozil efficacy vs pantetine in dyslipoproteinemic patients: a controlled study. Curr Ther Res 1989; 45: 650-663
• 23 O’Brien JR, Etherington MD, Shuttleworth RD, Adams CM, Middleton JE, Goodland FC. A pilot study on the effect of gemfibrozil on some haematological parameters. Thromb Res 1982; 26: 275-279
• 24 Schwartzkopff W, Menzel B, Stern K. Gemfibrozil in patients with primary hyperlipoproteinemias. Therapiewoche 1985; 35: 1388-1389
• 25 Stringer MD, Steadman CA, Kakkar VV. Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease. Some undiscovered actions. Curr Med Res Opin 1990; 12: 207-214
• 26 Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, Rosenberg RD, Miller GJ. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemostas 1992; 67: 503-506